Mazdutide vs Semaglutide
Extensively Studied vs FDA Approved
avoid Researched · 95% Both are GLP-1 agonists; combining increases hypoglycemia and severe GI side effect risk.
Molecular Data
Mazdutide Semaglutide
Weight 4,563.1 Da 4,113.64 Da
Half-life 6-8 days ~7 days (168 hours)
Chain 33 amino acids 31 amino acids
Type Oxyntomodulin analog with fatty acid conjugation GLP-1 receptor agonist
Key Benefits
Mazdutide
01 Up to 20% body weight loss
02 Superior glycemic control versus semaglutide
03 Increased energy expenditure via glucagon receptor activation
04 Improved cardiometabolic markers (BP, lipids, liver fat)
05 Once-weekly injection convenience
Semaglutide
01 15-20% average body weight reduction
02 Established cardiovascular protection
03 Convenient once-weekly dosing options
04 Comprehensive safety data from extensive trials
05 Flexible injectable and oral formulations
Dosing Protocols
Mazdutide
Start 1.5-3mg weekly, titrate up to 6-9mg based on response / Once weekly injection
Weight loss initiation (3mg target) 1.5mg → 3mg Once weekly
Weight loss progression (4.5mg target) 1.5mg → 3mg → 4.5mg Once weekly
Weight loss optimization (6mg target) 2mg → 4mg → 6mg Once weekly
Maximum weight loss (9mg target) 3mg → 6mg → 9mg Once weekly
T2D management (mild-moderate) 3-4.5mg weekly Once weekly
Semaglutide
0.25mg starting, titrate to 1-2.4mg weekly / Once weekly (same day each week)
Weight Loss Initiation 0.25mg Weekly x 4 weeks, then increase
Weight Loss Maintenance 2.4mg Weekly (after 16-week titration)
Diabetes Management 0.5-1mg Weekly
Cardiovascular Protection 0.5-1mg Weekly
Tolerability-Based 0.25-2.4mg Weekly (individualized)
Side Effects
Mazdutide
Nausea (mild-moderate, typically improves over time)
Diarrhea
Vomiting
Increased heart rate (5-17 bpm observed)
Semaglutide
Nausea
Diarrhea
Vomiting
Constipation
Abdominal pain
Contraindications
Personal or family history of medullary thyroid carcinoma
MEN2 syndrome history (class warning for GLP-1 agonists)
Pregnancy or breastfeeding (insufficient safety data)
Personal or family history of medullary thyroid cancer
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Pregnancy or breastfeeding
History of pancreatitis
Research Evidence
Mazdutide Semaglutide
Status Extensively Studied FDA Approved
References 4 studies 9 studies
Latest — 2025-06
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.